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ABSTRACT:
Phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) 
are two key components of the PI3K/Akt/mTOR signaling pathway. This signal 
transduction cascade regulates a wide range of physiological cell processes, that 
include differentiation, proliferation, apoptosis, autophagy, metabolism, motility, and 
exocytosis. However, constitutively active PI3K/Akt/mTOR signaling characterizes 
many types of  tumors where it negatively influences response to therapeutic 
treatments. Hence, targeting PI3K/Akt/mTOR signaling with small molecule 
inhibitors may improve cancer patient outcome. The PI3K/Akt/mTOR signaling 
cascade is overactive in acute leukemias, where it correlates with enhanced drug-
resistance and poor prognosis. The catalytic sites of PI3K and mTOR share a high 
degree of sequence homology. This feature has allowed the synthesis of ATP-
competitive compounds targeting the catalytic site of both kinases. In preclinical 
models, dual PI3K/mTOR inhibitors displayed a much stronger cytotoxicity against 
acute leukemia cells than either PI3K inhibitors or allosteric mTOR inhibitors, such 
as rapamycin. At variance with rapamycin, dual PI3K/mTOR inhibitors targeted 
both mTOR complex 1 and mTOR complex 2, and inhibited the rapamycin-resistant 
phosphorylation of eukaryotic initiation factor 4E-binding protein 1, resulting in 
a marked inhibition of oncogenic protein translation. Therefore, they strongly 
reduced cell proliferation and induced an important apoptotic response. Here, we 
reviewed the evidence documenting that dual PI3K/mTOR inhibitors may represent 
a promising option for future targeted therapies of acute leukemia patients.
INTRODUCTION
Acute leukemias comprise a heterogeneous group 
of malignant diseases that arise from immature cells of 
either myelogenous or lymphoid lineage. Leukemic 
cells are blocked at various stages of differentiation, 
and resistant to apoptosis. Thus, they accumulate in the 
bone marrow. This causes a progressive failure of normal 
hematopoiesis, which results in anemia, neutropenia, and 
thrombocytopenia. Each year, nearly 15,000 adult and 
pediatric patients in the United States are diagnosed with 
acute leukemia.
Acute myelogenous leukemia (AML) is a disorder 
with a median age of presentation in the late 60s. In 
younger patients, the incidence is two to three cases per 
100,000 individuals, however in the seventh and eighth 
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decade the incidence rises to 13 to 15 per 100,000 [1]. 
AML accounts for approximately 80% of all adult acute 
leukemias [2, 3]. Results of AML treatment have improved 
in younger patients who can tolerate intensified treatment 
strategies, however there have been very limited changes 
in outcome among individuals who are >60 years of age. 
Thus, the prognosis of AML remains poor, with an overall 
5-year survival rate of 15-30%, while patients older than 
60 years display an even worse prognosis (<10% survival 
at 5 years) [4].
Acute lymphoblastic leukemia (ALL) is caused 
by the uncontrolled clonal proliferation of immature 
lymphoid cells. In T-cell acute lymphoblastic leukemia 
(T-ALL), the malignant cells are derived in the thymus 
from T-cell progenitor cells and express immature T-cell 
immunophenotypic markers [5, 6]. T-cell neoplastic 
transformation is a complex process in which multiple 
lesions, involving both oncogenes and tumor suppressor 
genes, cooperate to alter the normal signaling pathways 
that regulate proliferation, differentiation, and survival of 
developing T-cells [7-10]. T-ALL comprises about 15% of 
pediatric and 25% of adult ALLs. T-ALL was associated 
with a very bad outcome, however the introduction of 
intensified polychemotherapy protocols has improved 
the prognosis of this disorder and current therapies can 
achieve 5-year relapse-free survival rates of about 75% in 
pediatric patients and 40-50% in adults [11, 12].
B-cell acute lymphoblastic leukemia (B-ALL) 
is by far the most common pediatric malignancy and 
comprises 85% of childhood ALL [13]. New therapeutic 
protocols have improved pediatric patient survival rate to 
approximately 80% at 5 years, however some cases still 
relapse and are tried by long-term side effects of therapy 
[14-16]. The overall prognosis of children with relapsed 
disease remains poor with less than 40% survival at 5 
years [17]. B-ALL is a heterogeneous disorder including 
several subtypes with specific cellular and molecular 
features, that are related to clinical outcome [18]. The 
Philadelphia (Ph) chromosome is the most common 
cytogenetic anomaly associated with adult B-ALL. The 
Ph chromosome results from a reciprocal translocation 
(t) between chromosomes 9 and 22 (t[9,22][q34;q11]) 
[19], and results in a fusion gene on chromosome 22, i.e. 
the breakpoint cluster region-Abelson leukemia (Bcr-
Abl) viral proto-oncogene. Bcr-Abl fusion proteins are 
constitutively active non-receptor tyrosine kinases that 
alter a myriad of intracellular signaling networks, thus 
contributing to leukemic cell proliferation and survival. 
The breakpoint may occur within one of four sites on the 
Bcr gene to yield three proteins of different sizes: p190, 
p210, and p230 [20]. The p190 Bcr-Abl fusion protein 
occurs in about 90% of children and between 50% and 
80% of adults with Ph+ B-ALL. The p210 Bcr-Abl gene 
constitutes the rest of the Ph+ B-ALL population, while 
p230 characterizes chronic myelogenous leukemia 
[18]. Until recently, Ph+ B-ALL patients treated with 
conventional chemotherapy carried a very poor prognosis 
irrespective of their age (approximately 10% survival at 5 
years). However, the outcome for patients with Ph+ B-ALL 
has improved substantially with the introduction of the 
tyrosine kinase inhibitor (TKI) imatinib in combination 
with chemotherapy [21]. Second generation TKIs 
(dasatinib, nilotinib) have displayed a promising activity 
in Ph+ B-ALL cases that developed resistance to imatinib 
due to Bcr-Abl mutations, although there are Bcr-Abl 
mutations, such as T315I, that are resistant to these novel 
TKIs [18; 22].
Since acute leukemias can still have an extremely 
poor outcome, at present great interest surrounds 
the development of novel and less toxic therapeutic 
strategies that may target aberrantly activated signaling 
networks involved in proliferation, survival, and drug-
resistance of leukemic cells [23]. One such pathway is 
represented by the phosphatidylinositol 3-kinase (PI3K)/
Akt/mammalian target of rapamycin (mTOR) signaling 
network. Several lines of evidence, obtained in preclinical 
settings of acute leukemias, have documented how this 
network could be targeted by small molecule protein 
kinase inhibitors [24-28]. Indeed, the PI3K/Akt/mTOR 
pathway is probably the most easily druggable signaling 
network in human neoplasias, and an impressive array of 
inhibitors, targeting critical components of this cascade, 
have been designed by drug companies [29]. However, 
optimal therapeutic strategies have yet to be identified for 
a successful treatment of acute leukemias. Inhibition of 
critical signaling nodes such as PI3K or mTOR induced 
cell cycle arrest, apoptosis, and lowered drug-resistance 
of leukemic cells [24-28]. Several phase I/II clinical trials 
are now underway, in which PI3K or mTOR inhibitors are 
being tested in leukemic patients [30-32]. In this review, 
we discuss the evidence documenting that dual PI3K/
mTOR inhibitors could represent a promising option for 
future targeted therapies of patients with acute leukemias.
LEUKEMIA INITIATING CELLS
A cancer stem cell model has been proposed 
for explaining malignant development, in analogy 
to physiological tissue renewal and differentiation. 
According to this model, many types of cancers, 
including acute leukemias, are organized hierarchically 
and their growth is sustained by a subpopulation of rare 
cancer stem cells (or cancer initiating cells) displaying 
asymmetric cell division, self-renewal capacity, and a 
limited differentiation potential [33, 34]. Cancer stem 
cells are mainly quiescent and intrinsically resistant to 
anticancer therapies. They can be serially transplanted into 
immunocompromised mice [typically nonobese diabetic 
(NOD)/severe combined immunodeficiency disease 
(SCID) mice] for generating tumors, and are responsible 
for the occurrence of metastases, drug-resistance, and 
relapses after induction chemotherapy or radiotherapy 
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of the primary tumor [35, 36]. In acute leukemias, these 
cells are referred to as leukemia stem cells or leukemia 
initiating cells (LICs) [37]. LICs were first identified in 
AML patients by the group of John Dick in Toronto [38]. 
It was initially thought that in AML, LICs resided solely 
in the CD34+/CD38- cell subset. Subsequent studies have 
highlighted that in some AML cases/subtypes, LIC activity 
was endowed in other cell subpopulations, displaying 
either a CD34-, or a CD34+/CD34- phenotype [39, 40], or 
even a CD34+/CD38+ phenotype [41, 42]. 
Furthermore, the xenograft assay allowed 
measurement of the LIC frequency: It was found to be 
on the order of one per million of leukemic cells [38]. 
Nevertheless, this number could be deceivingly low, 
because it was subsequently demonstrated that leukemias 
of murine origin transplanted into histocompatible 
recipients, displayed a LIC frequency of around one to ten 
[43, 44]. This could be a consequence of the limited ability 
Figure 1: The PI3K/Akt/mTOR signaling pathway. TKRs (for example, IGF-1R) stimulate class I PI3K activity. PI3K generates 
PtdIns 3,4,5P3 from PtdIns 4,5,P2. PtdIns 3,4,5P3 attracts to the plasma membrane PDK1 which phosphorylates Akt at Thr 308. Full Akt 
activation requires Ser 473 phosphorylation by mTORC2. Active Akt inhibits TSC2 activity through direct phosphorylation. TSC2 is a 
GTP-ase activating protein (GAP) that functions in association with TSC1 to inactivate the small G protein Rheb. Akt-driven TSC1/TSC2 
complex inactivation allows Rheb to accumulate in a GTP-bound state. Rheb-GTP then upregulates the protein kinase activity of mTORC1. 
mTORC1 targets p70S6K, 4E-BP1, S6RP, and eIF4B which are critical for mRNA translation. However, both mTORC1 and eIF4B are 
targeted also by the Ras/Raf/MEK/ERK pathway. p70S6K controls activation of both PI3K and Ras through an inhibitory loop which 
involves IRS-1/2. Arrows indicate activating events, whereas perpendicular lines highlight inhibitory events. 
Deptor: DEP-domain-containing mTOR interacting protein; 4E-BP1: eukaryotic initiation factor 4E-binding protein 1; eIF4B: eukaryotic 
initiation factor 4B; eIF4E: eukaryotic initiation factor 4E; ERK: extracellular signal-regulated kinase; IGF-1R: insulin-like growth 
factor-1 receptor; IRS-1/2: insulin receptor substrate 1/2; MEK: mitogen-activated protein kinase kinase; mLST8: mammalian Lethal-
with-Sec-Thirteen 8; mTOR: mammalian target of rapamycin; mTORC1: mTOR complex 1; mTORC2: mTOR complex 2; PDK1: 
phosphatidylinositol-dependent kinase 1; PI3K: phosphatidylinositol 3-kinase; PRAS40: proline-rich Akt substrate 40; Protor: protein 
observed with Rictor; PtdIns 4,5P2: PtdIns-4,5-bisphosphate; PtdIns 3,4,5P3: PtdIns-3-4,5-trisphosphate; p70S6K: p70S6 kinase; p90RSK: 
p90 ribosomal S6 kinase; Raptor: regulatory associated protein of mTOR; Rheb: Ras homolog enriched in brain; Rictor: rapamycin-
insensitive companion of mTOR; TRK: receptor tyrosine kinase; SIN1: stress-activated protein kinase-interacting protein 1; S6RP: S6 
ribosomal protein; TSC1: tuberous sclerosis 1; TSC2: tuberous sclerosis 2. 
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of human leukemic cells to adapt to grow in a more or less 
hostile murine microenvironment [45]. 
In T-ALL, multiple subpopulations endowed with 
LIC activity have been identified, including CD34+/
CD4-, CD34+/CD7-, CD34+/CD7+, CD34-/CD7+ [46, 47]. 
Intriguingly, CD34 is not always a marker of stemness in 
T-ALL patients, especially in adult patients [48].
In B-ALL, LICs were initially described to be 
enriched in the CD34+/CD19- cell subpopulation [46]. 
However, other groups have reported that LICs were 
comprised in the CD34+/CD19+ lymphoblast subset [49, 
50].
The data emerging from phenotypying studies of 
LICs are in agreement with recent studies, performed 
in ALL patients, that have highlighted the genomic 
heterogeneity of LICs. In the first study, the authors 
examined pediatric B-ALL cases displaying the ETS 
(E-twenty six) -variant gene 6/Runt-related transcription 
factor-1 (ETV6/RUNX-1) fusion gene in relation to the 
presence of genomic copy number alterations (CNAs) 
[51]. By exploiting techniques capable of single cell 
analysis, it was documented the highly heterogeneous and 
diverse clonal architectures of LICs, consistently with a 
branching, non-linear evolutionary history of leukemia 
development. Accordingly, genomic CNAs occurred 
in various leukemic subsets in no particular order and 
reiteratively at various stages of the disease. Importantly, 
clonal architecture was dynamic and changed in the 
lead-up to diagnosis and in relapses. LICs xenografted 
in mice displayed heterogeneous genetic alterations 
and proliferative capacities. In the second study, where 
genomic CNAs were investigated in patients with Ph+ 
B-ALL, the investigators reported very similar findings 
[52]. 
Regarding T-ALL, genome-wide profiling was used 
to compare samples at the time of diagnosis and after 
engraftment into recipient mice. Compared with paired 
diagnosis samples, the xenografted leukemias often 
contained additional genomic lesions in oncogenes and/
or tumor suppressor genes. Moreover, the xenografted 
leukemias appeared to arise from minor cell subsets 
existing in the patient at diagnosis [53]. These novel data 
imply that putative LICs are considerably more complex 
in their genomic alterations and biologic behavior than 
initially thought, and offer a theoretical basis for future 
attempts to develop effective individualized LIC-targeted 
therapies, that should take into account these differences 
[54].
The so-called side-population (SP) is thought to be 
enriched in cancer stem cells. SP cells actively extrude 
the nuclear acid-staining dye, Hoechst 33342, owing to 
high expression on their plasma membrane of transporters 
of the ATP-binding cassette (ABC) family, including 
ABCB1 and ABCG2, and can be easily identified by flow 
cytometry [55, 56]. As to acute leukemias, an enrichment 
of SP cells in LICs has been demonstrated in both AML 
[57], and T-ALL [58].
THE PI3K/Akt/mTOR PATHWAY
PI3Ks are a family of lipid kinases that 
phosphorylate the 3’-OH of phosphatidylinositols. These 
enzymes are grouped into three classes, each with distinct 
substrate specificity and lipid products: I, II, and III [59]. 
In mammalian cells, class I PI3Ks are the best understood 
PI3Ks and the most widely implicated in human 
neoplasias [60]. For this reason, they will be the only 
PI3Ks highlighted here. Class I PI3Ks are further divided 
into two subgroups: A and B. Class IA PI3Ks contain one 
of three catalytic subunits (p110α, p110β, p110δ) that form 
heterodimers with one of the five adaptor (or regulatory) 
isoforms (p85α, p85β, p55α, p55γ, p50α). In general, 
class IA PI3Ks are activated downstream of both tyrosine 
kinase receptors (TKRs) and G protein-coupled receptors 
(GPCRs). The single class IB PI3K comprises a p110γ 
catalytic subunit which binds one of two related regulatory 
subunits, p101, and p87. Class IB PI3Ks mainly act 
downstream of GPCRs, however they can be stimulated 
also by TKRs [61]. Only class I PI3Ks have the ability to 
use phosphatidylinositol-4,5-bisphosphate (PtdIns 4,5P2) 
to generate the second messenger, phosphatidylinositol-
3,4,5-trisphosphate (PtdIns 3,4,5P3).
Once activated by a variety of growth factors and 
cytokines, class I PI3Ks initiate a cascade of events 
that promote cancer cell proliferation, survival, and 
metabolism. Akt, a 57-kDa serine/threonine kinase, is a 
key effector of PI3K in carcinogenesis. Akt is a member of 
the AGC protein kinase family and is the cellular homolog 
of the v-akt oncogene. The Akt family includes three 
highly conserved isoforms: Akt1/α, Akt2/β, and Akt3/γ 
[62]. The recruitment of inactive Akt from the cytosol 
to the plasma membrane, requires that the pleckstrin 
homology (PH) domain of Akt binds to PtdIns 3,4,5P3 
synthesized at the plasma membrane by PI3K. Akt is 
then phosphorylated at Thr 308 by phosphatidylinositol-
dependent kinase 1 (PDK1), and at Ser 473 by mTOR 
complex 2 (mTORC2, see later on), resulting in full 
activation of Akt kinase activity [63] (FIGURE 1).
Akt phosphorylates a plethora of targets [61; 64, 65] 
on RxRxxS/T consensus motifs [66]. Intriguingly, most 
of the Akt effects depend on its ability to phosphorylate 
proteins involved in cell cycle progression, apoptosis, 
mRNA translation, glycolysis, and angiogenesis, thus 
unlocking most, if not all, of the critical processes 
involved in tumorigenesis [67].
mTOR is a 289-kDa serine/threonine kinase which 
belongs to the phosphatidylinositol 3-kinase-related kinase 
(PIKK) family [68]. mTOR encompasses two functionally 
distinct multiprotein complexes, referred to as mTOR 
complex 1 (mTORC1) and mTORC2. mTORC1 is a 
direct downstream effector of Akt (FIGURE 1), however 
its activity is controlled through other signaling networks 
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that include the Ras/Raf/mitogen-activated protein kinase 
kinase (MEK)/extracellular signal-regulated kinase (ERK) 
1/2 signaling network (FIGURE 2), and the liver kinase 
B1 (LKB1)/AMP-activated protein kinase (AMPK) 
cascade [69, 70]. 
mTORC1 is characterized by the interactions 
between mTOR and the regulatory associated protein 
of mTOR (Raptor), which regulates mTOR activity 
and functions as a scaffold for recruiting mTORC1 
substrates. mTORC1 is sensitive to rapamycin and its 
analogs (rapalogs) that include RAD-001, CCI-779, and 
AP23753. Rapamycin/rapalogs are allosteric mTORC1 
inhibitors and do not target the mTOR catalytic site [71, 
72]. They associate with the FK506 binding protein 12 
(FKBP-12, see [73]), and, by doing so, they induce the 
disassembly of mTORC1, resulting in inhibition of its 
activity [72]. Nevertheless, there are mTORC1 outputs, 
such as eukaryotic initiation factor 4E-binding protein 1 
(4E-BP1) phosphorylation (see later on), that are resistant 
to rapamycin/rapalogs, at least in some experimental 
models [74, 75].
mTORC2 comprises the rapamycin-insensitive 
companion of mTOR (Rictor) and is generally described as 
being insensitive to rapamycin/rapalogs. However, long-
term (>24 hours) treatment of about 20% of cancer cell 
lines (mainly of hematopoietic lineage) with rapamycin/
rapalogs resulted in  mTORC2 activity inhibition [76, 77]. 
mTORC1 controls translation in response to growth 
factors/nutrients through the phosphorylation of p70S6 
kinase (p70S6K) and 4E-BP1. p70S6K phosphorylates 
the 40S ribosomal protein, S6 (S6RP), leading to active 
translation of mRNAs [78]. Furthermore, p70S6K 
phosphorylates the eukaryotic initiation factor 4B (eIF4B) 
which is critically involved in translation [79, 80]. 
However, eIF4B is a downstream target also of MEK/ERK 
signaling [81] (FIGURE 1). Unphosphorylated 4E-BP1 
interacts with the cap-binding protein, eukaryotic initiation 
factor 4E (eIF4E), and prevents the formation of the 4F 
translational initiation complex (eIF4F), by competing for 
the binding of eukaryotic initiation factor 4G (eIF4G) to 
eIF4E. 4E-BP1 phosphorylation by mTORC1 results in 
the release of the eIF4E, which then associates with eIF4G 
to stimulate translation initiation [82]. eIF4E is critical 
for translating 5’capped mRNAs, that include transcripts 
mainly encoding for proliferation and survival promoting 
proteins, such as c-Myc, cyclin-dependent kinase-2 
(CDK-2), cyclin D1, signal activator and transducer of 
transcription-3 (STAT-3), B-cell lymphoma (Bcl) -2, Bcl-
xL, survivin, myeloid cell leukemia-1 (Mcl-1), ornithine 
decarboxylase [76; 82, 83]. 
Moreover, mTORC1 represses autophagy, a 
lysosome-dependent degradation pathway which allows 
cells to recycle damaged or superfluous cytoplasmic 
content, such as proteins,  lipids, and organelles [84]. As 
a consequence, cells produce metabolic precursors for 
macromolecular biosynthesis or ATP generation. In cancer 
cells, autophagy fulfils a dual role, because it can have 
both tumor-suppressing and tumor-promoting functions. 
Indeed, the autophagic machinery prevents necrosis and 
inflammation, that can lead to genetic instability and 
tumorigenesis. However, autophagy might be important 
for tumor progression, by providing energy through 
its recycling mechanism during unfavorable metabolic 
circumstances, that are very common in tumors [85].
The mechanisms that control mTORC2 activity 
have only begun to be revealed [86], however mTORC2 
activation by growth factors requires PI3K, as 
pharmacological inhibition of PI3K decreased mTORC2 
activity in vitro [87]. mTORC2 phosphorylates Akt at Ser 
473 which enhances subsequent Akt phosphorylation on 
Thr 308 by PDK1. 
PI3K, Akt, and mTORC1/2 are linked to each 
other via regulatory feedback loops, that restrain their 
simultaneous hyperactivation [76]. A negative regulation 
of Akt activity by mTORC1 is dependent on p70S6K-
mediated phosphorylation of insulin receptor substrate 
(IRS) -1 and -2 adapter proteins, downstream of the 
insulin receptor (IR) and/or insulin-like growth factor-1 
receptor (IGF-1R) [88-90]. IRS-1 and IRS-2 are normally 
required to activate class IA PI3Ks after stimulation of IR/ 
IGF-1R tyrosine kinase activity. When mTORC1 is active, 
p70S6K phosphorylates the IRS-1 and -2 proteins on Ser 
residues, targeting them for proteasomal degradation 
[91, 92]. Therefore, inhibition of mTORC1 signaling by 
rapamycin/rapalogs blocks this negative feedback loop 
and activates Akt through PI3K (FIGURE 1). Recent 
findings have highlighted the existence of a rapamycin-
sensitive, mTORC1/p70S6K-mediated phosphorylation 
of Rictor at Thr 1135. This phosphorylative event exerted 
a negative regulatory effect on the mTORC2-dependent 
phosphorylation of Akt in vivo [93]. Thus, both mTORC1 
and mTORC2 could control Akt activation. 
PI3K/Akt/mTOR signaling is negatively regulated 
by lipid and protein phosphatases. Phosphatase and tensin 
homolog (PTEN) is a lipid phosphatase which removes the 
3’-phosphate from PtdIns 3,4,5P3, thereby antagonizing 
PI3K signaling [94, 95]. Two other lipid phosphatases, Src 
homology domain-containing inositol phosphatase (SHIP) 
1 and 2, remove the 5-phosphate from PtdIns 3,4,5P3 to 
yield PtdIns 3,4P2 [96]. Protein phosphatase 2A (PP2A) 
downregulates Akt activity directly, by dephosphorylating 
it at Thr 308 and several lines of evidence indicates that 
PP2A is a tumor suppressor [97]. Moreover, Ser 473 Akt 
is dephosphorylated by the two isoforms (1 and 2) of PH 
domain leucine-rich repeat protein phosphatase (PHLPP). 
Decreased PHLPP activity has been linked to specific 
cancer types [98, 99].
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PI3K/Akt/mTOR signaling in acute leukemias
AML
Activation of PI3K/Akt/mTOR signaling is a 
common event in AML patients. Akt phosphorylation 
at Ser 473, assayed by either western blotting or flow 
cytometry analysis of leukemic cells, could be detected 
in 50-80% of AML patients [100-103]. Less data are 
available regarding Thr 308 p-Akt. However, this amino 
acid residue is phosphorylated in most AML patients 
[104-105], and Akt phosphorylation at Thr 308, but not 
at Ser 473, correlated with a poorer prognosis of AML 
patients [104]. Interestingly, Akt phosphorylation at 
Ser 473 could be detected in the CD34+/CD38-/CD123+ 
leukemic cell subset which is enriched in LICs [106]. 
mTORC1 is activated in almost all (95%) of primary AML 
samples, as documented by phosphorylation of p70S6K 
and 4E-BP1 at Thr 389 and Thr 37/46, respectively [107, 
108]. Since mTORC2 phosphorylates Akt at Ser 473, 
it is likely to be activated in most primary AML cells. 
The mechanisms leading to PI3K activation in AML 
cells have been partially clarified. In most cases, either 
p110β or p110δ (or both) PI3K could be involved in 
Akt phosphorylation [109-111]. Intriguingly, it has been 
demonstrated that IGF-1/IGF-1R signaling activates 
PI3K in about 70% of AML cases. Indeed, leukemic 
cells express functional IGF-1R, and an IGF-1 autocrine 
production is detectable in AML primary cells [110; 
112, 113]. Accordingly, downregulation of either p110β 
or p110δ PI3K by RNA interference (siRNA) impaired 
IGF-1-stimulated Akt activation, and negatively affected 
proliferation and survival of AML cells [110]. Similar 
findings were reported in a study in which the IGF-1/IGF-
1R autocrine loop was blocked by neutralizing antibodies 
to IGF-1R or by siRNA to IGF-1 [114]. Other TKRs that 
could be involved in activating PI3K in AML, include 
mutated (constitutively active) FMS-like tyrosine kinase 
3 (FLT-3) and c-Kit. However, statistical association 
between FLT3-ITD (internal tandem duplication, which 
leads to receptor constitutive activation, see [115]) or 
c-Kit mutations and PI3K signaling upregulation, has not 
been reported in primary AML cells [116]. Nevertheless, 
it has been demonstrated that GRB-2-associated binder 
(GAB-2), which is frequently overexpressed in AML 
[117, 118], could mediate PI3K activation downstream of 
some mutant c-Kit receptors. Alterations in the activity of 
the PTEN and SHIP phosphatases might activate PI3K in 
AML, however PTEN and SHIP1 inactivating mutations/
deletions are exceedingly rare in this disease [119]. 
Phosphorylation and decreased expression of PTEN have 
been reported in AML patients, however their significance 
remains highly controversial [120]. Recent findings have 
highlighted that there exists a inverse relationship between 
the expression levels of the B55α regulatory subunit 
of the PP2A phosphatase (which functions as an Akt 
phosphatase, see [121]) and the Thr 308 (but not Ser 473) 
Akt phosphorylation levels in AML primary cells. This 
finding suggested that B55α dephosphorylates Akt at Thr 
308, but not Ser 473, in AML cells [122]. Interestingly, this 
study reported lower levels of the PP2A B55α regulatory 
subunit in AML primary cells when compared with CD34+ 
bone marrow cells from healthy donors. 
Another report has documented that PP2A 
activity downregulation is a recurrent event in AML 
patients. The downregulation could be related to PP2A 
hyperphosphorylation at Tyr 307 in 78% of the analyzed 
cases. Overexpression of two endogenous PP2A inhibitors 
[SET (Su(var)3-9 and ‘Enhancer of zeste’ proteins, from 
which the acronym SET is derived), and SETBP1, a SET-
binding protein] correlated with high levels of Tyr 307 
phosphorylation in 55% of the cases. In some patients, the 
authors detected decreased expression of PP2A regulatory 
subunits (PPP2R1B, PPP2R5B, PPP2R5C). Thus, PP2A 
decreased activity in AML could be due to multiple 
mechanisms [123]. In any case, restoration of PP2A 
activity with forskolin decreased Akt phosphorylation at 
Thr 308 [123]. Intriguingly, the same group had previously 
documented that SETBP1 associated with SET and PP2A, 
thus forming a multi-protein complex which inhibited 
PP2A activity. This complex enhanced proliferation 
of the leukemic cells. However,  the effects on Akt 
phosphorylation levels had not been analyzed [124]. 
Other potential mechanisms of PI3K/Akt activation 
in AML could be autocrine/paracrine secretion of vascular 
endothelial growth factor (VEGF) or angiopoietin [125, 
126]. Indeed, an emerging theme in leukemia biology, 
regards the interactions between leukemic cells and cells 
of the bone marrow microenvironment, that include 
stromal cells, adipocytes, and osteoblasts [127]. These 
cells secrete a plethora of growth factors, cytokines, and 
other molecules, that could then impact on PI3K/Akt 
signaling in leukemic cells. The interactions between 
fibronectin (which is secreted by stromal cells) and the 
very late antigen-4 (VLA-4, expressed by leukemic cells) 
activated PI3K/Akt and increased drug-resistance in 
AML primary cells [128]. VLA-4 is formed by α4 and 
β1 integrin and is a key regulator of adult hematopoiesis 
[129]. VLA-4 increased PI3K/Akt signaling, because 
the integrin linked kinase (ILK), which interacts with 
β-integrins, is another kinase which phosphorylates Akt 
on Ser 473. Indeed, bone marrow-derived stromal cells 
induced both ILK and Akt activation in leukemic cells and 
QLT0267, an ILK inhibitor, blunted stromal cell-induced 
Ser 473 Akt phosphorylation [130]. 
The mechanisms leading to constitutive mTORC1 
activation in primary AML blast cells are at present 
unclear. Several studies have demonstrated that 
constitutive mTORC1 activation could be PI3K-
independent because: 1) in about 50% of AML primary 
samples, mTORC1 was activated, whereas PI3K/Akt was 
not [131]; 2) the p110δ PI3K selective inhibitor, IC87114, 
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downregulated PI3K/Akt but did not suppress mTORC1 
activity [116]; 3) the Src kinase Lyn was constitutively 
phosphorylated in some AML patients and controlled 
mTORC1, but not Akt, activation [132]; 4) inhibition 
of the IGF-1/IGF-1R autocrine loop with anti-IGF-1R 
antibodies inhibited Akt, but not p70S6K, phosphorylation 
[114]; 5) mTORC1 activity in AML samples could be 
decreased by inhibiting MEK/ERK signaling [133]. In 
this connection, it is very important to emphasize here that 
MEK/ERK activation is a very common event in AML 
patients [134]. 
T-ALL
PI3K/Akt/mTOR signaling upregulation is very 
common in T-ALL, being detectable in 70-85% of the 
patients [135], and portends a poorer prognosis [136]. 
Similarly to AML, multiple mechanisms could lead 
to PI3K/Akt/mTOR increased activity in T-ALL cells. 
Much attention has been  devoted to PTEN, since the 
initial report by Ferrando and coworkers documenting 
that PTEN gene expression was inactivated in T-ALL cell 
lines and patients displaying Notch-1 activating mutations, 
through a repressive mechanism mediated by Hairy and 
Enhancer of Split homolog-1 (HES-1) [137-139]. In 
T-ALL cell lines, PTEN loss correlated with resistance 
to Notch inhibitors, raising concerns that patients with 
PTEN-negative disease could not respond to Notch 
inhibitor therapy [138]. However, it has been subsequently 
demonstrated that PTEN loss did not relieve primary 
T-ALL cells of their “addiction” to Notch-1 signaling 
[140]. It has been reported that PTEN downregulation 
could be a consequence also of miR-19 overexpression, 
which resulted in lower expression of several genes 
controlling the PI3K/Akt/mTOR cascade, including 
PTEN [141]. Furthermore, in a zebrafish model of T-ALL, 
c-Myc, which is typically overexpressed downstream of 
activated Notch-1 in T-ALL [142], caused PTEN mRNA 
downregulation [143].
Nevertheless, in most T-ALL clinical samples PTEN 
is expressed, but is inactivated due to phosphorylation by 
casein kinase 2 (CK2) and/or oxidation by reactive oxygen 
species (ROS), which results in overactive PI3K/Akt/
mTOR signaling [135]. 
Mutations in PI3K, Akt, PTEN, and SHIP1 have 
been described in T-ALL patients. However, their 
frequency is very low and their functional significance 
with regard to PI3K/Akt/mTOR activation, has not been 
thoroughly assessed [144, 145].
IGF-1/IGF-1R signaling plays an important role in 
the activation of the PI3K/Akt/mTOR cascade in T-ALL 
cells, as pharmacologic inhibition or genetic deletion of 
IGF-1R blocked T-ALL cell proliferation and survival 
[146]. Interestingly, IGF-1R is a Notch-1 target gene and 
Notch-1 was required to maintain IGF-1R expression 
at high levels in T-ALL cells. Furthermore, a moderate 
decrease in IGF1-R signaling compromised T-ALL LIC 
activity [146]. 
In T-ALL, cytokines produced by the thymic/
bone marrow microenvironment could be involved 
in upregulation of PI3K/Akt/mTOR signaling. These 
include interleukin (IL) -4 [147], and IL-7 [148, 149]. In 
particular, it has been recently reported that ROS produced 
by IL-7, are critical for activating PI3K/Akt/mTOR which 
then mediates proliferation and survival of T-ALL cells 
[150]. A source for IL-7 could be represented also by 
thymic epithelial cells [151]. However, increased signaling 
downstream of the IL-7 receptor (IL-7R) in T-ALL 
patients, could be a consequence of gain-of-function IL-
7R mutations, which are detected in about 9% of T-ALL 
pediatric patients [152].
Another cytokine with the potential for activating 
PI3K/Akt/mTOR signaling is the CXC chemokine ligand 
12 (CXCL12), referred to as SDF-1a (stromal cell-
derived factor 1a), the ligand for the CXC chemokine 
receptor 4 (CXCR4) [153]. CXCL12 is produced by bone 
marrow stromal cells in T-ALL patients [154] and has 
been recently demonstrated to be involved in PI3K/Akt 
activation and drug-resistance in T-ALL cells [155].
It is not clear whether mTORC1 could be activated 
by signaling pathways other than PI3K/Akt in T-ALL 
cells. IL-7 activates MEK/ERK in T-ALL primary cells, 
however pharmacological inhibition of MEK/ERK did 
not have any negative effects on cell cycle progression 
and survival [148]. Thus, the pathophysiological relevance 
of MEK/ERK activation in T-ALL needs to be further 
investigated. In any case, MEK/ERK upregulation is 
observed in about 38% of adult T-ALL patients [156].
B-ALL
In Ph+ B-ALL, the Bcr-Abl tyrosine kinase is 
upstream of the PI3K/Akt/mTOR pathway [157-161]. 
Bcr-Abl associates with a number of proteins (c-Cbl, 
Shc, GRB-2, and GAB-2) that bind the p85α subunit of 
PI3K [162], resulting in its activation [163]. Accordingly, 
the Bcr-Abl inhibitor imatinib downregulated mTORC1 
activity in Ph+ chronic myelogenous leukemia cells 
[164], while Ph+ B-ALL cell lines were hypersensitive to 
rapamycin [165].
PI3Ks play a key role in Bcr-Abl-dependent models 
of murine leukemogenesis. Indeed, it was possible to 
create mice that had Pik3r1 (p85α/p55α/p50α) deleted 
specifically in the B-cell lineage and Pik3r2 (p85β) deleted 
in all cells. As a consequence, there was decreased p190 
Bcr-Abl-mediated in vitro colony transformation of both 
α- and α-/β- progenitor B-cells. Moreover, p190+/α-/β- 
B-cells displayed a severe loss of leukemogenic potential 
in vivo [166]. However, it was found that either genetic 
or pharmacological (wortmannin, LY294002) inhibition 
of PI3K only partially reduced mTORC1 activity, as 
assessed by phosphorylation of S6RP in these cells. 
To explore the mechanism of PI3K/Akt-independent 
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mTORC1 regulation, the authors investigated the role of 
two other potential mTORC1-controlling pathways: MEK/
ERK and amino acid sensing. Basal ERK phosphorylation 
was consistently elevated in α-/β- leukemic colony forming 
cells (L-CFCs) and blocked by treatment with a MEK 
inhibitor [166]. Nevertheless, MEK inhibition did not 
affect mTORC1 activity, as judged by phosphorylation 
of 4E-BP1, while p-S6RP levels were modestly reduced 
in both control and α-/β- L-CFCs, most likely due to 
stimulatory effects of ERK on p70S6K [167]. When the 
contribution of amino acid sensing by withdrawal of 
leucine from the culture media was assessed, mTORC1 
activity was rapidly extinguished in α-/β- L-CFCs, as 
reported in other cell systems [168]. Amino acid sensing 
by mTORC1 was promoted by class III PI3K (hVPS34), 
an enzyme whose activity is sensitive to wortmannin 
[169]. This might explain the partial inhibition of 
mTORC1 signaling by wortmannin in α-/β- L-CFCs that 
lack class IA PI3Ks. Therefore, residual mTORC1 activity 
in α-/β- L-CFCs was MEK/ERK-independent and sustained 
by amino acid sensing and, perhaps, other pathways that 
remain to be defined [166].
There are however, Bcr-Abl-independent 
mechanisms of PI3K activation that resulted in imatinib 
resistance [170], but they have not been analyzed 
thoroughly.
Another reason for enhanced PI3K/Akt/mTOR 
signaling in Ph+ B-ALL is due to the fact PP2A is 
functionally inactivated during the blast crisis of 
chronic myelogenous leukemia through the inhibitory 
activity of SET protein, which is regulated by Bcr-
Abl [171]. Reactivation of PP2A activity by FTY720 
(fingolimod, a PP2A activator which has been approved 
as an immunomodulator for oral use in patients with 
multiple sclerosis [172]), led to leukemic cell growth 
suppression, enhanced apoptosis, impaired clonogenicity, 
and decreased in vivo leukemogenesis of imatinib- and 
dasatinib-sensitive and -resistant Ph+ B-ALL cells, as well 
as Ph+ B-ALL progenitors (CD34+/CD19+). Importantly, 
healthy CD34+ and CD34+/CD19+ bone marrow cells 
were unaffacted by FTY720. Moreover, pharmacologic 
doses of FTY720 suppressed in vivo Bcr-Abl-driven 
leukemogenesis (including leukemogenesis promoted by 
the T315I Bcr-Abl mutant which is resistant to imatinib 
and second generation TKIs) without exerting any toxicity 
in mice [173].
In Ph- B-ALL cases, the mechanisms for PI3K/Akt/
mTOR upregulation are unclear, however, they could 
be dependent on activation of signaling downstream of 
cytokine receptors, through interactions of leukemic cells 
with bone marrow stromal cells [174-178]. Interestingly, 
pediatric B-ALL patients with high expression of VLA-4 
displayed an adverse outcome, which might be related to 
activation of PI3K/Akt/mTOR signaling [179]. Moreover, 
gain-of-function mutations in IL-7R have been identified 
in pediatric Ph- B-ALL cases [180], that could account 
for pathway activation. Very recently, it has been shown 
that ETV6/RUNX1 silencing abrogated PI3K/Akt/
mTOR signaling in pediatric precursor B-ALL, however, 
no mechanistic explanation for this phenomenon was 
presented [181].
PI3K/AKT/mTOR signaling in LICs
The concept that the PI3K/Akt/mTOR signaling 
may serve as a therapeutic target in LICs is beginning 
to emerge. Over the last six years, several manuscripts 
have focused on the effects of PI3K/Akt/mTOR signaling 
activation in hematopoietic stem cells (HSCs) with 
regard to the development of malignant hematopoietic 
disorders, including acute leukemias. In a conditional 
PTEN knockout murine model, upon inactivation of 
PTEN, there was a transient increase in HSCs followed 
by a myeloproliferative neoplasia (MPN), and the mice 
subsequently developed an acute myeloid/lymphoid 
leukemic-like disease after 4-6 weeks [182, 183]. 
However, if the mice had been pretreated with rapamycin, 
the MPN and leukemia did not develop. The preleukemic 
cells that arose after conditional PTEN deletion by 
themselves were not able to induce acute leukemia upon 
transfer into SCID-recipient mice, but if the leukemic 
cells were derived from the PTEN- conditional mice that 
had already developed overt leukemia, they were able 
to transfer leukemia to the mice, which could not be 
prevented by rapamycin treatment. The healthy HSCs 
from the PTEN conditional knockout mice repopulated 
the hematopoietic cell compartment of irradiated mice 
treated with rapamycin, indicating that it was possible 
to selectively eliminate preleukemic cells before the 
onset of an overt leukemia [183]. Consistently, Guo 
and coworkers [184], using a murine model of PTEN- 
T-ALL, have documented that long-term rapamycin 
treatment of preleukemic mice prevented LIC formation 
and halted T-ALL development. Nevertheless, rapamycin 
did not inhibit mTORC1 signaling in the c-Kitmid/CD3+/
Lin- population already enriched for LICs and did not 
eliminate these cells. These observations may indicate that 
when an acute leukemia had expanded, LICs had already 
developed additional genetic anomalies, that could prevent 
the therapeutic efficacy of rapamycin, as highlighted 
by a previous paper documenting that multi-genetic 
events collaboratively contributed to PTEN- T-ALL LIC 
formation [185]. 
In another study, a conditional PTEN knockout mice 
was crossed with a myeloid-specific Cre line in which the 
Cre recombinase gene was inserted into the endogenous 
M lysozyme locus, and therefore was under the control 
of myeloid-specific lysozyme promoter. Therefore, only 
in the myeloid linage there was a disruption of PTEN 
expression. In mice older than three months, an acute 
leukemia (resembling human acute monocytic leukemia, 
i.e. a subset of AML) was observed in 11 of 18 cases 
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examined [186]. Moreover, PTEN functions as a tumor 
suppressor in Ph+ LICs [187]. Indeed, in murine models 
of Bcr-Abl-induced chronic myelogenous leukemia, 
PTEN was downregulated and PTEN deletion caused an 
accelerated development of the disorder. Overexpression 
of PTEN suppressed LICs, delayed the development of 
Ph+ B-ALL, and prolonged mice survival. These PTEN 
effects were mediated through Akt1. Overall, these 
findings supported the concept that PTEN plays a key 
role in the development of Ph+ B-ALL through PI3K/Akt/
mTOR signaling [187]. As to other components of the 
PI3K/Akt/mTOR signaling pathway, p85α PI3K has been 
demonstrated to be involved in oncogenic c-Kit-induced 
transformation in AML, in an murine model where p85α 
PI3K expression was disrupted in HSCs. In contrast, p85β 
PI3K disruption had no functional consequences [188]. 
TARGETING PI3K/Akt/mTOR SIGNALING 
AND ACUTE LEUKEMIAS
The fungal metabolite wortmannin and LY294002 
are two well-known and isoform non-selective PI3K 
inhibitors. These drugs block the enzymatic activity 
of PI3K by different mechanisms. Wortmannin is an 
irreversible inhibitor (IC50≈2 nM) which forms a covalent 
bond with a conserved lysine residue involved in the 
phosphate-binding reaction [189], whereas LY294002 is 
a classical reversible, ATP-competitive PI3K modulator 
(IC50=1.40 μM) [190]. In spite of the crossover inhibition 
of other kinases (for example, LY294002 inhibits mTOR 
and CK2 with equal potency) and their unfavorable 
pharmaceutical properties, both wortmannin and 
LY294002 have served as important research tools for 
more than a decade in elucidating the role of PI3K in the 
biology of human cancers [191].
Wortmannin and LY294002 have been widely used 
in preclinical models of human acute leukemias, where 
they induced cell cycle arrest and apoptosis, as well as 
lowered drug-resistance to traditional chemotherapeutic 
drugs [100; 178; 192-195].
Given the important role played by p110δ PI3K in 
PI3K/Akt activation in AML, this isoform could represent 
a good target for pathway inhibition. IC87114, a selective 
p110δ PI3K inhibitor, decreased cell proliferation and 
survival in AML cells, and increased sensitivity to 
etoposide [109; 113; 196]. CAL-101 is an oral p110δ 
PI3K inhibitor currently undergoing clinical evaluation 
in patients with B-cell malignancies [197]. In vitro, it 
displayed significant cytotoxic activity in 23% of B-ALL 
samples tested, but only in 3% of AML samples. CAL-
101 dephosphorylated Thr 308 p-Akt, and induced 
apoptosis in neoplastic B-cells [197]. Remarkably, CAL-
101 did not affect in a substantial manner the survival 
of healthy B-, T-, and natural killer (NK) lymphocytes 
[198]. However, it was found that CAL-101 inhibited 
production of inflammatory cytokines, such as IL-6, 
IL-10, tumor necrosis factor (TNF) -α (produced by 
T-lymphocytes), and interferon (IFN)-γ (synthesized by 
NK lymphocytes). Therefore, it remains to be established 
whether decreased production of TNF-α and IFN-γ would 
impair inflammatory responses in B-ALL patients treated 
with CAL-101. 
Rapamycin/rapalogs have been widely used 
both in vitro and in vivo in preclinical settings of acute 
leukemias, where they blocked cell proliferation and 
induced, sometimes, apoptosis and/or autophagy 
[100; 174; 199, 200] [201-203]. Moreover, several 
studies have highlighted that both PI3K and mTOR 
modulators could synergize with a wide range of drugs 
that are currently in use for treating acute leukemias, 
including chemotherapeutic drugs [108; 192, 193; 204], 
glucocorticoids [205-206], histone deacetylase inhibitors 
[207], ionizing radiation [208], proteasome inhibitors 
[208], all-trans-retinoic acid [193], and arsenic trioxide 
(As2O3) [209, 210].
A fundamental observation which has emerged 
from preclinical studies with PI3K or mTOR inhibitors, 
is that leukemic cells/LICs are usually more sensitive to 
pathway inhibition than healthy leukocytes or HSCs [108; 
135; 211]. This indicates that a therapeutic window might 
exist which would allow the use of these drugs in humans, 
without serious side effects, at least at the hematopoietic 
system level. 
Rapamycin/rapalogs have been tested in a few phase 
I/II studies in patients with AML, but the results have been 
quite disappointing [107; 212-214]. Nevertheless, there 
are numerous ongoing clinical trials in which allosteric 
mTORC1 inhibitors are being tested in patients with acute 
leukemias, mostly in combination with other drugs (http://
clinicaltrials.gov).
DUAL PI3K/mTOR INHIBITORS
PI-103, a morpholino quinazoline derivative, was 
the first disclosed ATP-competitive kinase inhibitor of 
mTOR which blocked the enzymatic activity of PI3K p110 
isoforms, but displayed good selectivity over the rest of 
the human kinome [215]. PI-103 is a pan-class I PI3K 
inhibitor with IC50 values in the 2 nM (p110α PI3K) to 15 
nM range (p110γ PI3K) [215-216]. It was demonstrated 
that PI-103, as other dual PI3K/mTOR inhibitors, inhibited 
both mTORC1 (IC50=0.02 μM) and mTORC2 (IC50=0.083 
μM) [215;217]. Several other similar compounds have 
subsequently been released, including NVP-BEZ235 
[217], XL765 [218], PKI-587 [219], PF-04691502 [220], 
WJD008 [221], PKI-402 [222], and GNE-477 [223].
The kinase selectivity profile of these dual PI3K/
mTOR modulators is consistent with the high sequence 
homology and identity in the ATP-catalytic cleft of these 
kinases. Dual PI3K/mTOR inhibitors have displayed 
significant, concentration-dependent cell proliferation 
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inhibition and induction of apoptosis in a broad panel of 
cancer cell lines, including those harboring PI3K p110α 
activating mutations [224]. Overall, the in vitro activity of 
these ATP-competitive PI3K/mTOR modulators translated 
well in in vivo models of human cancer xenografted in 
mice. They were well tolerated and achieved tumor stasis 
or even regression when administered orally [191]. In spite 
of their high lipophilicity and limited water solubility, the 
pharmacological, biological and preclinical safety profiles 
of these dual PI3K/mTOR inhibitors supported their 
clinical development and a few of them (NVP-BEZ235, 
for example) are currently undergoing phase I/II clinical 
trials in cancer patients [75].
DUAL PI3K/mTOR INHIBITORS AND ACUTE 
LEKEMIAS
PI-103
Quite a few studies have highlighted that PI-103 may 
be of therapeutic value in acute leukemias. As to AML, it 
has been documented that the inhibitor, when used alone 
in AML cell lines, blocked cell cycle progression in the G1 
phase and a displayed a modest proapoptotic activity [225]. 
However, when combined with nutlin-3 (a small molecule 
inhibitor of the murine double minute (MDM) -2/p53 
interactions, see [226]), PI-103 enhanced p53-dependent 
apoptosis in AML cell lines and primary cells expressing 
wild-type p53. Interestingly, PI-103 considerably 
enhanced proapoptotic Bax conformational change by 
nutlin-3 in the p53 wild-type AML cells, suggesting 
that PI3K/mTOR inhibition enhanced the p53-mediated 
mitochondrial apoptotic pathway. However, it has been 
highlighted that mTOR inhibition by PI-103 resulted in 
downregulation of p53 protein synthesis at the mRNA 
translational level. Interestingly, PI-103 treatment resulted 
in decreased expression of many pro- and antiapoptotic 
proteins. Levels of downstream transcriptional targets of 
p53 including MDM-2, p21, and Noxa were decreased. 
Noxa is a major p53-induced proapoptotic member of the 
Bcl-2 family proteins [227]. Levels of the antiapoptotic 
proteins Bcl-2 and survivin were decreased, whereas 
Puma, and Bax levels did not change significantly [225]. 
Cooperative dephosphorylation of the translational 
repressor 4E-BP1 by PI-103 and nutlin-3 indicated that 
mTOR inhibition and p53 activation strongly disrupted 
mTORC1-mediated translational control, resulting in 
imbalanced expression of pro- and antiapoptotic proteins 
and unstable mitochondrial membrane potential. PI-103 
induced cleavage of caspase-3, which was enhanced by 
nutlin-3 cotreatment, in p53 wild-type OCI-AML-3 cells. 
PI-103 synergized with doxorubicin [225].
Another study has confirmed that PI-103 was 
essentially cytostatic for AML cell lines and blocked cells 
in the G1 phase of the cell cycle. However, in primary AML 
cells, PI-103 not only inhibited leukemic cell proliferation, 
but induced mitochondrial apoptosis, especially in a cell 
subset (CD34+/CD38-/CD123+) enriched in LICs [228]. 
While PI-103 affected the clonogenicity of leukemic 
progenitors, it did not induce apoptosis in CD34+ cells 
from healthy donors and had moderate effects on their 
proliferative and clonogenic properties. These findings 
suggested the possible existence of a therapeutic window 
in vivo if PI3K/mTOR inhibitors were used to treat 
leukemic patients. PI-103 displayed additive proapoptotic 
effects with etoposide in blast cells and in the CD34+/
CD38-/CD123+ leukemic subpopulation [228]. More 
recently, it has been documented that PI-103 synergized 
with As2O3 in non-acute promyelocytic leukemia (APL) 
primary cells. As2O3 transiently upregulated PI3K/Akt/
mTOR signaling in non-APL leukemic blasts and cell 
lines, and this increase could be blocked by PI-103 
[229]. A combined As2O3/PI-103 treatment strongly 
synergized to kill non-APL cells and promoted their 
differentiation in vitro, as demonstrated by increased 
expression of CD11b and CD14 granulocytic/monocytic 
surface markers. Importantly, As2O3/PI-103 combined 
treatment led to a loss of the potential of LICs (CD34+/
CD38-) to regenerate non-APL leukemia in NOD/SCID 
mice. The eradication of LICs was, at least in part, due 
to the profoundly enhanced induction of differentiation 
in vivo. Furthermore, the As2O3/PI-103 combination was 
almost non-toxic to hematopoietic stem cells from healthy 
bone marrow. It should be emphasized here that although 
differentiating therapy with As2O3 is very successful 
in APL, non-APL cases do not respond to this kind of 
therapy [230]. Therefore, the results reported by Hong et 
al. [229] appear very encouraging, as they indicate that 
As2O3 might be exploited as a new therapeutic strategy 
for targeting non-APL patients in combination with dual 
PI3K/mTOR inhibitors.
PI-103 has been studied in a preclinical setting of 
T-ALL, where it induced both cell cycle arrest in the G1 
phase of the cell cycle and caspase-dependent apoptosis, at 
variance with rapamycin, which was mainly cytostatic. PI-
103 was more effective than selective inhibitors of p110α, 
p110β, p110γ, and p110δ PI3K. Unlike rapamycin, PI-103 
dephosphorylated Ser 473 Akt, which was indicative of 
mTORC2 inhibition. Remarkably, PI-103 treatment of 
T-ALL cell lines resulted in a marked dephosphorylation 
of 4E-BP1 at Thr 37/46, which was not detected with 
rapamycin [231]. Accordingly, PI-103 targeted protein 
translation more effectively than rapamycin [232]. In 
T-ALL cell lines, PI-103 synergized with vincristine, a 
chemotherapeutic drug which is employed for treating 
T-ALL patients [233]. Of note, PI-103 was cytotoxic 
not only to T-ALL cell lines, but affected the viability of 
T-ALL primary cells. Thus, these findings indicated that 
multitargeted therapy toward PI3K and mTOR might serve 
as an efficient treatment for those T-ALL patients that 
display upregulation of PI3K/Akt/mTOR signaling [231]. 
The antileukemic efficacy of PI-103 has been 
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documented, both in vitro and in vivo, in Ph+ leukemia 
cells. Indeed, the drug was more effective than rapamycin 
at suppressing proliferation of mouse Ph+ pre-B-ALL co-
treated with the TKI, imatinib [166]. The greater efficacy 
of PI-103 than rapamycin, could be explained by the fact 
that rapamycin induced a short time (6 hours) feedback 
rebound of p-Akt levels, which was not seen when cells 
were treated with PI-103. The findings from the murine 
model were then extended to human leukemias, using 
primary CD34+/CD19+ cells purified from peripheral blood 
of patients with Ph+ or Ph- B-ALL. When their clonogenic 
potential was assessed, Ph- B-ALL samples were resistant 
to imatinib, as expected. However, in each case of Ph+ 
B-ALL, the presence of PI-103 combined with imatinib 
suppressed colony formation to a greater extent than 
imatinib alone or imatinib in combination with rapamycin. 
Remarkably, PI-103 could potentiate the antileukemic 
effect of imatinib in samples derived from patients who 
were clinically resistant to this TKI [166]. However, it 
has been subsequently reported that PI-103 displayed an 
immunosuppressive effect in mouse in vivo, consisting 
of a reduction of the fraction of B-cells with a germinal 
center phenotype, a dose-dependent displacement of 
marginal zone B-cells, and a drop in the percentages of 
total splenic B- and T-cells [234]. Therefore, the potential 
immunosuppressive effects of dual PI3K/mTOR inhibitors 
should be carefully evaluated in future studies.
NVP-BEZ235
PI-103 displayed a remarkable efficacy in vitro 
and in vivo in preclinical settings of human and mouse 
neoplasias, however, its pharmacological features were 
found to be unfavourable, so any further development for 
its use in humans has been precluded [235]. NVP-BEZ235 
is an orally bioavailable drug containing a tricyclic 
imidazo quinoline core scaffold, which has entered phase 
I/II clinical trials for solid tumors [217]. Recently, its 
efficacy has been tested against human AML cell lines 
and primary samples [236]. NVP-BEZ235 inhibited PI3K, 
mTORC1, and mTORC2 signaling, as demonstrated by 
the dephosphorylation of paxillin, a read-out for mTORC2 
activity [237]. Furthermore, NVP-BEZ235 fully inhibited 
the rapamycin-resistant phosphorylation of 4E-BP1, 
causing a marked inhibition of protein translation in AML 
cells. This resulted in reduced levels of the expression of 
three highly oncogenic proteins known to be regulated 
at the translation initiation level, i.e. c-Myc, cyclin D1, 
and Bcl-xL [238]. Hence, NVP-BEZ235 reduced the 
proliferation and induced an important apoptotic response 
in AML cells without affecting healthy CD34+ cell 
survival. Moreover, it affected the clonogenic activity of 
leukemic, but not healthy, CD34+ cells [236].
NVP-BEZ235 was cytotoxic to a panel of T-ALL cell 
lines and caused cell cycle arrest, apoptosis, and autophagy. 
Western blots documented a dose- and time-dependent 
dephosphorylation of Akt and mTORC1 downstream 
targets in response to NVP-BEZ235 [239]. Remarkably, 
NVP-BEZ235 targeted the SP of both T-ALL cell lines 
and patient lymphoblasts, which might correspond to 
LICs, and synergized with several chemotherapeutic 
agents (cyclophosphamide, cytarabine, dexamethasone) 
currently used for treating T-ALL patients. NVP-BEZ235 
reduced chemoresistance to vincristine induced in Jurkat 
cells by coculturing with MS-5 stromal cells, that mimic 
the bone marrow microenvironment [240]. NVP-BEZ235 
was cytotoxic to T-ALL patient lymphoblasts displaying 
pathway activation, where the drug dephosphorylated 4E-
BP1, at variance with rapamycin. Taken together, these 
findings indicated that longitudinal inhibition at two nodes 
of the PI3K/Akt/mTOR network with NVP-BEZ235, 
either alone or in combination with chemotherapeutic 
drugs, may be an efficient treatment of those T-ALL cases 
that have aberrant upregulation of this signaling pathway 
[239]. Antiproliferative effects of NVP-BEZ235 in ALL 
cells were associated with reduced levels of cyclin-
dependent kinase 4 and cyclin D3 [241]. 
NVP-BEZ235 has been evaluated in a mouse model 
consisting of BA/F3 cells overexpressing either wild-type 
Bcr-Abl or its imatinib-resistant mutant forms (E255K 
and T315I) [242]. NVP-BEZ235 inhibited proliferation 
of both wild-type and mutant Bcr-Abl overexpressing 
cells, whereas parental Ba/F3 cells were much less 
sensitive. The drug induced apoptosis, and inhibited both 
mTORC1 and mTORC2 signaling. Remarkably, the drug 
displayed cytotoxic activity in vivo against leukemic cells 
expressing the E255K and T315I Bcr-Abl mutant forms 
[242]. However, in this experimental model NVP-BEZ235 
induced an overactivation of MEK/ERK signaling, most 
likely due to the well-known compensatory feedback 
mechanism that involves p70S6K [243]. 
NVP-BAG956
This drug was originally described as a dual PI3K/
PDK1 inhibitor [244], however it was subsequently 
disclosed that it inhibited mTOR [245]. NVP-BAG956 
blocked Akt phosphorylation induced by Bcr-Abl and 
caused apoptosis of Bcr-Abl-expressing cell lines and 
patient bone marrow cells at concentrations that inhibited 
PI3K signaling. Enhancement of the inhibitory effects of 
the TKIs, imatinib and nilotinib, by NVP-BAG956 was 
demonstrated against Bcr-Abl expressing cells both in 
vitro and in vivo. It was documented that NVP-BAG956 
was effective against mutant FLT3-expressing cell lines 
and AML patient bone marrow cells. Enhancement of the 
inhibitory effects of the TKI, PKC412, by NVP-BAG956 
was demonstrated against mutant FLT3-expressing cells. 
Finally, NVP-BAG956 and rapamycin/RAD001 were 
shown to combine in a non-antagonistic fashion against 
Bcr-Abl- and mutant FLT3-expressing cells both in vitro 
and in vivo [244].
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CONCLUSIONS AND FUTURE 
PERSPECTIVES
Several lines of evidence have documented that 
PI3K and mTOR are key nodes in the PI3K/Akt/mTOR 
signaling cascade, which is by far the most commonly 
upregulated pathway in human cancers, including acute 
leukemias [246-253]. Several major pharmaceutical 
companies are currently testing the hypothesis that 
dual PI3K/mTOR inhibitors, used either alone or in 
combination with other drugs, will be able to overcome 
the limited clinical responses that have been observed 
with PI3K-selective inhibitors or rapamycin/rapalogs 
[254-256]. The findings reviewed in this article suggest 
that there is a strong rationale for targeting both PI3K and 
mTOR in acute leukemias. Indeed, it should be considered 
that mTORC1 could be activated by signaling pathways 
other than PI3K/Akt/mTOR (MEK/ERK, for example), 
hence mTORC1 activity could escape the inhibition of 
signals downstream of PI3K, as reported in AML [116]. 
Dual PI3K/mTOR inhibitors target both mTORC1 and 
mTORC2, and are powerful suppressors of cell cycle 
progression and inducers of apoptosis, most likely because 
they efficiently block translation of short-lived oncogenetic 
proteins [257, 258]. Moreover, in most experimental 
models dual PI3K/mTOR inhibitors did not cause the Akt 
hyperactivation which is often detected when rapamycin/
rapalogs are employed in anti-cancer therapies [259]. 
However, there are two reports that have documented 
that NVP-BEZ235 resulted in MEK/ERK overactivation 
in Bcr-Abl-expressing murine cells [242], and in human 
glioblastoma-like stem cells [260]. Indeed, it is now clear 
that PI3K/Akt/mTORC1 and MEK/ERK pathways repress 
each other through a p70S6K-mediated negative feedback 
loop [260]. Therefore, this is an issue that will require 
further investigation in models of human acute leukemias, 
as it could indicate the need for combining dual PI3K/
mTOR inhibitors with MEK inhibitors. Furthermore, dual 
PI3K/mTOR inhibitors are pan-PI3K p110 inhibitors, and 
this could represent an additional advantage over selective 
PI3K isoform inhibitors, as in both AML and T-ALL more 
than one PI3K p110 isoform is usually active. 
PI3K has numerous roles in cell survival, 
differentiation, metabolism and migration, some of which 
are independent of mTOR [60; 261]. Therefore, it remains 
to be determined whether simultaneous inhibition of 
PI3K and mTOR will provide an acceptable therapeutic 
window in humans. For example, we do not know the in 
vivo toxicity of dual PI3K/mTOR inhibitors towards the 
immune system and hematopoiesis. Could it be possible 
to specifically target PI3K/Akt/mTOR signaling in LICs, 
without affecting the functions of HSCs? Indeed, evidence 
suggests that this pathway is important for the biology of 
normal stem cells, including HSCs [32; 69; 262-264]. 
NVP-BEZ235 did not display detrimental effects in vitro 
on healthy T-lymphocytes proliferation or the clonogenic 
activity of normal CD34+ hematopoietic progenitor cells 
[236; 239]. Nevertheless, results from Fruman’s laboratory 
seem to indicate that PI-103 suppressed hematopoietic 
colony formation and B-cell proliferation more strongly 
than an mTORC1/mTORC2 kinase inhibitor [234]. A 
recent report documented that PI-103 lowered lymphocyte 
numbers in vivo and suppressed immune rejection of 
melanoma xenografts [265]. It remains to be established 
whether the different effects displayed by NVP-BEZ235 
and PI-103 on healthy lymphocytes and hematopoietic 
cells were related to the different experimental models or 
reflected the different chemical structure of these drugs.
However, there are preliminary data indicating 
that there exist subtle differences in how HSCs and 
LICs utilize the same signaling pathways. This has been 
demonstrated in LICs treated with rapamycin [183]. In 
this case, the drug did not affect HSCs, whereas it was 
cytotoxic to LICs. These observations have provided the 
proof-of-principle that functional differences in signaling 
pathways between neoplastic and healthy stem cells could 
be identified and exploited for targeted therapy. Ultimately, 
the most efficacious use of any kind of signal transduction 
modulator will be in the context of personalized medicine 
[266]. Indeed, if LICs are to be successfully targeted in 
clinical settings of acute leukemias, this will require a 
comprehensive understanding of how signaling pathways 
function in cancer cells when compared to their healthy 
counterpart. Therefore, a major challenge in the clinical 
use of PI3K/Akt/mTOR pathway inhibitors will be the 
identification of patients who will likely respond to the 
treatment. For example, it has been recently documented 
that high levels of the cell cycle progression inhibitor, 
p27Kip1, sensitized pituitary adenomas to NVP-BEZ235 
[267], whereas amplification of either c-Myc or eIF4E 
rendered breast cancer cells resistant to NVP-BEZ235 
[268]. Intriguingly, c-Myc is frequently overexpressed 
in T-ALL [269], whereas increased expression levels of 
eIF4E have been recently reported in AML [270].
Thus, a thorough evaluation of cross-talks between 
signaling pathways aberrantly activated in LICs coupled 
to the identification of specific PI3K/Akt/mTOR substrates 
and of their roles in the quiescence, proliferation, survival, 
and drug-resistance of LICs as compared with HSCs, 
could provide the rationale for developing personalized 
pharmacological treatments, based on dual PI3K/mTOR 
inhibitors, aimed to acute leukemia eradication. 
Therefore, also acute leukemias could be added 
to the growing list of disorders where PI3K and mTOR 
inhibition could be beneficial to patients [271-276]. 
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